View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Angi Inc. to Announce Q4 2025 Earnings on February 10th and Host Earni...

Angi Inc. to Announce Q4 2025 Earnings on February 10th and Host Earnings Conference Call on February 11th DENVER, Jan. 20, 2026 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, February 10, 2026, Angi Inc. (NASDAQ: ANGI) will post its fourth quarter results and publish CEO Jeff Kip's letter to shareholders, which may include certain forward-looking information, at ir.angi.com/quarterly-earnings. On Wednesday, February 11, 2026, at 8:30 a.m. ET, Angi Inc. will host a conference call to answer questions regarding the company’s fourth quarter results. The live audiocast an...

 PRESS RELEASE

Millennials Are Driving the Future of Home Spending, According to Angi...

Millennials Are Driving the Future of Home Spending, According to Angi’s State of Home Spending Report New data finds Millennials spend more per household on home projects overall than any other generation, reshaping how Americans maintain, upgrade, and live in their homes. DENVER, Jan. 20, 2026 (GLOBE NEWSWIRE) -- reveals that Millennials have become the primary drivers of today’s home projects economy, generating the highest total home spending per household of any generation. While Millennials are not yet the largest group of homeowners, they outspend all other generations on a per-...

 PRESS RELEASE

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare C...

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco.  Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time. The fireside chat will be webcast live and available for replay in the Investors sectio...

G-III Apparel Group Ltd: 1 director

A director at G-III Apparel Group Ltd sold 34,693 shares at 31.740USD and the significance rating of the trade was 83/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

 PRESS RELEASE

G-III Apparel Group, Ltd. Reports Third Quarter Fiscal 2026 Results an...

G-III Apparel Group, Ltd. Reports Third Quarter Fiscal 2026 Results and Updates Fiscal 2026 Outlook; Initiates First Ever Quarterly Dividend Program Net Income Per Diluted Share of $1.84 and Non-GAAP Net Income Per Diluted Share of $1.90 for the Third Quarter, Both Exceeding GuidanceNet Sales of $988.6 Million for the Third QuarterRaises GAAP and Non-GAAP Net Income Per Diluted Share GuidanceMaintains Strong Cash and Availability PositionIntroduces First Ever Quarterly Dividend of $0.10 Per Share NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- G-III Apparel Group, Ltd. (NasdaqGS: GIII) (“G-I...

 PRESS RELEASE

G-III Apparel Group Announces Date for Third Quarter Fiscal 2026 Resul...

G-III Apparel Group Announces Date for Third Quarter Fiscal 2026 Results NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- G-III Apparel Group, Ltd. (NASDAQ: GIII) today announced that it will release its third quarter fiscal 2026 earnings before the market opens on Tuesday, December 9, 2025. Management will host a conference call to discuss results at 8:30 a.m. ET that same day, followed by a question and answer session for the investment community. To participate via telephone, please register in advance at this link: . Upon registration, all telephone participants will receive a confirmatio...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Opko Health Inc: 1 director

A director at Opko Health Inc bought 580,000 shares at 1.326USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

 PRESS RELEASE

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare...

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time. Investors interested in scheduling a meeting with OPKO management should conta...

 PRESS RELEASE

Angi Inc. Earnings Release and Letter to Shareholders Available on Com...

Angi Inc. Earnings Release and Letter to Shareholders Available on Company’s Website DENVER, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Angi Inc. (NASDAQ: ANGI) posted its third quarter financial results and a letter to shareholders from CEO, Jeffrey Kip on the investor relations section of its website at ir.angi.com/quarterly-earnings. As announced previously, Angi Inc. will host a conference call to discuss the company’s third quarter results and to answer questions. The call will be held on Wednesday, November 5, 2025, at 8:30 a.m. ET. Jeffrey Kip, CEO and Andrew Russakoff, CFO will participate...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 31, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

OPKO Health Reports Third Quarter 2025 Business Highlights and Financi...

OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Regeneron’s...

 PRESS RELEASE

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration wi...

OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multi...

 PRESS RELEASE

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for ...

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein  Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced the initiation and recent dosing of the first patient in a Phase 1/2a clinical trial () with MDX2004, a first-in-class trispecific antibody-fusion protein for oncology...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch